Blunt Roy sold $158K of THC

Blunt Roy sold 600 shares of TENET HEALTHCARE CORP (THC) at $262.68 ($0.16M total) on 2026-08-05.

Original reporting
SEC EDGAR · Blunt Roy
Published Aug 8, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 12:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates the insider activity record for Tenet Healthcare but does not include any operational, financial, or regulatory development.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context on total holdings, prior sales cadence, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07 after sale dated 2026-08-05

Background

The filing is an SEC Form 4 insider transaction by a Tenet Healthcare director, reporting an open-market sale of shares.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Blunt Roy filed a Form 4 selling 600 shares at $262.68 on 2026-08-05, totaling about $157.6K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider sales are common and often pre-planned; the filing provides transaction size and price but no accompanying company-specific news or guidance change.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification, taxes, or liquidity needs and may not reflect bearish expectations, especially without any other negative company news.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider sale disclosure.

  • Blunt Roy

    Director who sold 600 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.